Galectin Therapeutics Inc Ratios

Ratios Dec2011 Dec2012 Dec2013 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin 135,291.67%4,136.90%15,280.46%26,971.26%6,270.96%3,807.65%1,455.37%859.84%
EBIT Margin 135,391.67%4,048.21%15,445.98%26,947.13%6,171.57%3,712.68%1,363.61%765.94%
EBITDA Margin 135,391.67%4,048.21%15,445.98%26,947.13%6,171.57%3,712.68%1,363.61%765.94%
Operating Margin 135,391.67%4,048.21%15,445.98%26,947.13%6,171.57%3,712.68%1,363.61%765.94%
Net Margin 145,558.33%4,478.27%23,194.25%27,128.74%6,277.71%3,763.12%1,604.76%851.99%
FCF Margin 132,433.33%3,029.46%12,468.97%23,679.31%4,970.96%3,006.39%1,181.95%754.51%
Leverage & Solvency
Interest Coverage Ratio -0.00M-40.48-154.46-269.47-61.72-37.13-13.64-7.66
Times Interest Earned -0.00M-40.48-154.46-269.47-61.72-37.13-13.64-7.66
Valuation
Enterprise Value 73.98M32.73M147.96M119.03M141.10M162.69M127.85M122.84M67.15M102.67M80.96M
Market Capitalization 73.98M32.73M147.96M119.03M141.10M162.69M127.85M122.84M67.15M102.67M80.96M
Return Ratios
Return on Sales 41.37%152.80%269.71%62.71%38.08%14.55%8.60%